Previous 10 | Next 10 |
CorMedix, Inc. (CRMD) Q3 2019 Earnings Conference Call November 14, 2019 16:30 ET CompanyParticipants Dan Ferry - MD, LifeSci Advisors Khoso Baluch - CEO Phoebe Mounts - EVP & General Counsel Jack Armstrong - EVP, Technical Operations Bob Cook - CFO Conference Call Par...
CorMedix (NYSEMKT: CRMD ): Q3 GAAP EPS of -$1.35 misses by $1.14 . Revenue of $0.06M (-83.8% Y/Y) misses by $0.19M . Shares -1.4% . Press Release More news on: CorMedix, Inc., Earnings news and commentary, Healthcare stocks news, ,
BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial result...
BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will rep...
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the Company...
Thinly traded micro cap CorMedix (NYSEMKT: CRMD ) is up 5% premarket on light volume in response to its announcement that it has completed its interactions with the FDA regarding the Chemistry, Manufacturing and Controls (CMC) data package that will support its New Drug Applica...
BERKELEY HEIGHTS, N.J., Oct. 16, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has comp...
InsiderInsights' Daily Round-Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most ...
The following slide deck was published by CorMedix, Inc. in conjunction with this Read more ...
BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix m...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...